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Abstract  
PURPOSE: Uncontrolled seizures negatively impact the quality of life of epilepsy patients, and bone 
health represents one of the more serious adverse outcomes of epilepsy and its treatment. The objectives 
of this study were to determine the association between seizure status and bone metabolism and to 
determine the association between seizure status and the history of fractures. 
METHODS: A retrospective case-controlled study was conducted. Patient data was collected at the 
Comprehensive Epilepsy Center at the University of Kansas Medical Center (CEC KUMC). Adult 
patients with a positive diagnosis of epilepsy (age range 21-50) treated with at least one antiepileptic drug 
for more than six months were included in the study sample. Patients with a diagnosis of psychogenic 
nonepileptic seizures, obesity, abnormal liver transaminases, comorbidities and concomitant medications 
that alter bone metabolism were excluded from participation. The patients’ alkaliphosphatase (ALP) level 
was used as a biomarker for bone metabolism. The case was defined as ALP levels higher than the 
median ALP levels among the epilepsy patients at the CEC KUMC or positive history of fracture. 
Logistic regression was used to assess the association and to account for potential confounders.  
RESULTS: Among 2,607 patients, 161 patients were eligible for this study: 85 cases and 76 controls 
were identified. Patients with uncontrolled seizures demonstrated 1.964 times higher odds of ALP 
elevation relative to the odds of ALP elevation among epilepsy patients with well-controlled seizures 
(95% CI: 1.049-3.680, p=0.0341). Therapeutic category and proportion of enzyme-inducing AEDs were 
independent risk factors that altered ALP levels. The number of comorbidity, the number of concomitant 
medications, and the length of epilepsy were considered potential confounders. No association was found 
between seizure status and prevalence of fractures. 
CONCLUSIONS: Uncontrolled seizure status is a significant risk factor for alteration of bone metabolism 
when liver transaminases are normal. Further investigation is necessary to determine the influence of 
vitamin D intake on ALP elevation and uncontrolled seizures.
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Introduction 
Refractory seizures negatively impact the quality of life of epilepsy patients. A refractory seizure 
is defined as “having at least 1 seizure per month and having not responded positively to at least 2 
antiepileptic drugs (AEDs)”.
1
 Approximately 30% of epilepsy patients have experienced refractory 
seizures.
2-5
 One report shows  that almost 10% of patients with epilepsy never become seizure-free with a 
trial of a third AED or multiple AEDs.
6
 Despite the availability of multiple AEDs, optimizing seizure 
treatment remains difficult.  
Bone health in patients with epilepsy is a major concern. The fracture risk is two times to six 
times greater among patients with epilepsy compared to the general population.
7
 Although fractures may 
occur as a consequence of seizures, adverse effects of AED treatment and changes in brain function due 
to seizures negatively impact bone health.
8,9
  Numerous studies demonstrate that all AEDs alter various 
biomarkers of bone damage.
7,8,10-37
 Some AEDs induce isoenzymes, resulting in rapid metabolism and 
less bioavailability of endogenous and exogenous vitamin D and sex hormones.
38
  These hormones are 
essential in maintaining bone quality and in remodeling.
39,40
 Moreover, changes in brain function interfere 
with the regulation of the hypothalamus-pituitary-endocrine gland axis and its feedback system.
41
 
Therefore, patients with epilepsy have several risk factors for fractures. 
Fractures significantly reduce quality of life and limit physical activities.
42
 Moreover, 
expenditures for fracture treatment are costly.
43
 Current costs for fracture treatment secondary to 
osteoporosis are reported to be $19 billion in the United States and are predicted to increase to $25.3 
billion by 2025.
43
 Thus, appropriate fracture prevention and risk reduction among patients with epilepsy 
are critical to improving quality of life. 
Published studies demonstrate an association between AED use or duration of AED treatment and 
negative bone-health outcomes. However, none of the studies has determined the association between 
seizure severity and bone health. The aim of this study was to determine if patients with uncontrolled 
seizures show higher alkaline phosphatase (ALP) levels, the biomarker for bone formation, compared to 
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epilepsy patients whose seizures were well controlled. Also, we conducted an investigation to determine 
if uncontrolled seizures increased the risk for fractures. 
Methods 
Database 
All data were collected from the Comprehensive Epilepsy Center at the University of Kansas 
Medical Center, and 2,607 charts were reviewed. Monthly seizure frequency, gender, race (Caucasian, 
African American, and others), history of fractures, diagnosis date of epilepsy based on the International 
Classification of Diseases, Ninth Revision code or ICD9 code (345.XX), last office visit date, age, 
smoking status, vitamin D and calcium (Ca) intake, length of epilepsy, utilization of Vagus Nerve 
Stimulator (VNS), the number of AEDs and their daily doses, the number of concomitant medications and 
comorbidities, weight, and height were obtained for the study. Seizure frequency was captured during the 
patients’ most recent clinic visit. Uncontrolled seizure status is defined as when a patient experiences at 
least one seizure per month despite trials of two or more AEDs.
1
 Seizure-free is defined as “a patient has 
to be seizure free for at least 1 year, or 3 times the longest inter-seizure interval (whichever is longer).”
44
 
In this study, seizure frequency was used as a marker of seizure status, regardless of the number of current 
or previous AEDs. The reason for this was that patients did not remember the number of previous AED(s) 
correctly or that previous AEDs were not listed in a referral letter. If the daily dosage of AED was more 
than the recommended dose listed in the Anatomical Therapeutic Chemical classification system and the 
Defined Daily Dose (ATC/DDD) provided by World Health Organization,
48
 the dose was classified as 
high. The compliance rate of AEDs was calculated as follows: 28 days minus a number of AED missing 
days, then divided by 28 days. A compliance rate of 80% or more was considered as good medication 
compliance. Body mass index (BMI) was calculated as body weight in kilograms divided by height in 
meters squared. Laboratory data collected were ALP, alanine aminotransferase (ALT), aspartate 
aminotransferase (AST), serum calcium concentration, and vitamin D levels. Alkaline phosphatase is a 
frequently tested isoenzyme and usually is measured with other liver function tests, ALT, AST, and 
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gamma glutamyl transpeptidase. Approximately 50% of total ALP is derived from the liver and another 
50% from the bone.
45
 Bone ALP is produced by the surface of osteoblasts, making ALP elevation an 
indicator of bone formation, when other liver function tests are within a normal range.
39,46,47
 
Patient selection 
 Figure 1 showed the algorithm of patient selection. Of the 2,607 patients, those who met the 
following conditions were included in this sample: a positive diagnosis of epilepsy  (generalized [345.0x, 
345.1x, 345.2x, or 345.3x], partial [345.4x, 345.5x, or 345.7x]; or unclassified [345.8x or 345.9x]); aged 
21-50 at the last visit; treated with at least one AED for more than six months; and with liver function 
tests (ALP, ALT, and AST) within a year from the last clinic visit. Additionally, it was necessary for the 
study that female patients experienced a monthly menstrual cycle. A patient having what we refer to as an 
uncontrolled seizure status was a patient who had one or more seizures per month. Likewise, seizure free 
was defined as not having a seizure at least one year after the previous clinic visit.  
 Excluded from the study were patients with a diagnosis of psychogenic nonepileptic seizures 
(nonepileptic seizure or pseudo seizure); patients with obesity (defined as a BMI of 30 or greater); 
patients whose ALT and AST levels exceed 1.5 times above the upper normal range; patients with 
comorbidities that alter ALP levels, vitamin D levels, and bone metabolism (e.g., menopause, liver 
disease, viral hepatitis, renal disease, chronic kidney disease, pancreatic diseases, primary 
hyperparathyroidism, hyperthyroidism, inflammatory conditions, rheumatoid arthritis, Paget’s disease, 
osteoporosis, alcoholism); patients treated with medications that alter bone metabolism except AEDs 
(e.g., glucocorticoid, immunosuppressants, gonadotropin-releasing hormone analogues; and patients with 
chronic use of heparin, warfarin, chemotherapy agents, medroxyprogesterone acetate, diuretics, 
metoclopramide, methotrexate, and antiretroviral therapy for HIV). Also excluded were patients who did 
not have laboratory data within one year of the last visit as well as patients whose seizure frequency was 
not recorded in their chart or whose monthly seizure frequency was less than 1.  
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Figure 1: The algorithm of patient selection for the primary outcome. 
Case-control study design 
To assess the association between ALP elevation and seizure frequency among adult epilepsy 
patients, a retrospective case-control analysis was conducted using the data described in the previous 
section. Two categorical variables were examined as outcomes: ALP elevation and the history of 
fractures. The ALP elevation was defined as ALP levels higher than the median ALP levels among the 
epilepsy patients at the Comprehensive Epilepsy Center at the University of Kansas Medical Center. If a 
patient ever experienced fractures in lifetime and was listed on the charts, it was counted as a positive 
history of fracture.   
Statistical Analysis 
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Statistical analysis was performed using SAS version 9.3 (Cary, NC, United States). Differences 
in categorical variables, such as diagnosis (generalized epilepsy, partial epilepsy, or unclassified); gender; 
race (White, Black, or other); BMI (underweight, normal, or overweight); smoking status (smoker or 
nonsmoker); seizure status (controlled, defined as seizure free for more than one year, vs. uncontrolled, 
defined as having a seizure at least once a month); length of epilepsy (0-1 year, 1-10 years, 11-20 years, 
21-30 years, and more than 30 years); vitamin D intake (none, multivitamin, or vitamin D supplement 
defined as taking at least 400 IU daily); calcium intake (none, multivitamin, Ca supplement, defined as 
taking at least 500 mg daily); serum Ca levels (cutoff point: median value); ALP categorical (cutoff point: 
median value); history of fracture; compliance rate of AEDs (cutoff point: 80%); use of VNS; proportion 
of enzyme-inducing AEDs (EIAEDs: none, 0%-50%, more than 50%); proportion of high-dose of AEDs 
(high-dose defined as utilization of AED dose higher than the one listed in the ATC/DDD 
48
: none, 0%-
50%, more than 50%) were tested by Chi Square test or Fisher exact test where appropriate. Differences 
in continuous variables, (e.g., age, serum Ca levels, ALP, number of comorbidity, number of concomitant 
medication, and number of treatment AEDs) were tested by independent two sample t test, Student’s t test 
or Wilcoxon Rank Sum test where appropriate. P values of less than 0.05 were considered statistically 
significant.  
The primary endpoint of this study was to detect the difference in ALP elevation between 
controlled and uncontrolled seizure patients. The secondary outcome was to detect the association 
between uncontrolled seizures and the history of fractures. To assess the association between ALP 
elevation/the history of fracture and the variables, unadjusted odds ratios (OR) with 95% confidence 
intervals (CI) were calculated in logistic regression. The p values of less than 0.05 were considered as 
associated with ALP elevation/the history of fracture. In the logistic regression, if the coefficient value of 
uncontrolled seizure (β1) was altered by another variable by more than 10% compared with the β1 without 
the variable in the model, then the variable was considered a potential confounder. The Cochran-Mantel-
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 aenszel statistics were used to analyze how degrees of variables affect the value of the association (e.g., 
absence or present, dose differences).  
Furthermore, logistic regression was used for the calculation of crude and adjusted OR for ALP 
elevation (categorical) and the history of fracture. The logistic regression model was as follows, according 
to the hypothesis of previous reports regarding bone health among epilepsy patients
7,8,10-37
: 
Logit (p) of ALP elevation = intercept + β1x refractory seizure + β2x age + β3x gender + β4x number of comorbidity + β5x 
number of concomitant medication + β6x length of epilepsy + β7x vitamin D intake + β8x Ca intake + β9x serum Ca level + β10x number of AED 
+ β11x proportion of enzyme inducing AED + β12x therapeutic category.  
Also: Logit (p) of history of fracture = intercept + β1x refractory seizure + β2x age + β3x gender + β4x number of 
comorbidity + β5x number of concomitant medication + β6x length of epilepsy + β7x vitamin D intake + β8x Ca intake + β9x serum Ca level + 
β10x number of AED + β11x proportion of enzyme inducing AED.+ + β12x therapeutic category  + β13x alp elevation. 
Age and gender were included as covariates. The final multivariate model included variables when they 
were retained in a backward analysis with a p value of 0.10.  
Boluk and colleagues demonstrated that ALP levels among healthy adults and adult epilepsy 
patients were 95±36 IU/L and 111±32 IU/L, respectively.
49
 Based on their data, a group sample size was 
calculated, and 73 patients in each group (total sample size of 146) provided 80% power to detect a 
difference of ALP between two groups.  
Results 
A. Uncontrolled seizures and ALP elevation 
The study cohort was a total of 161 patients: 85 cases and 76 controls (Figure 1). The 
demographic characteristics were summarized in Table 1. No statistically significant differences were 
found between the cases and controls in age, diagnosis, race, BMI, length of epilepsy, vitamin D intake, 
Ca intake, serum Ca levels (continuous and categorical), number of concomitant medications, medication 
compliance rate, number of treatment AEDs, proportion of high-dose AEDs, and history of fractures. A 
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statistically significant difference was found in seizure status, gender, therapeutic category (monotherapy 
vs. polytherapy), VNS use, and proportion of EIAEDs. 
Table 1. Characteristics of Cases and Control Subjects 
 Cases: ALP ≥ 70 
(N=85) 
Controls: ALP < 70 
(N=76) 
P value 
Seizure status,  % (N) 
Seizure free 
Uncontrolled 
 
41.2 (35) 
58.8 (50) 
 
57.9 (44) 
42.1 (32) 
0.0341 
Age (median), years 33.0  32.0  0.4872 
Gender, % (N) 
Male 
Female 
 
68.2 (58) 
31.8 (27) 
 
37.6 (32) 
62.4 (44) 
0.0009 
Diagnosis,  % (N) 
Partial 
Generalized 
Unclassified 
 
77.7 (14) 
16.5 (14) 
5.9 (5) 
 
84.2 (64) 
14.5 (11) 
1.3 (1) 
0.2887 
Race, % (N) 
White 
Black 
Others 
 
84.7 (72) 
14.1 (12) 
1.2 (1) 
 
80.4 (61) 
17.1 (13) 
2.6 (2) 
0.6876 
BMI, % (N) 
Underweight 
Normal 
Overweight 
 
37.6 (32) 
31.8 (27) 
30.6 (26) 
 
28.9 (22) 
44.7 (34) 
26.3 (20) 
0.2295 
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Smoking,  % (N) 
Nonsmoker 
Smoker 
 
75.3 (64) 
24.7 (21) 
 
80.3 (61) 
19.7 (15) 
0.4500 
Medication compliance, % (N) 
≥ 80% 
< 80% 
 
92.9 (79) 
7.1 (6) 
 
93.4 (71) 
6.6 (5) 
0.4500 
Length of epilepsy, year 
1-10 years 
11-20 years 
21-30 years 
> 30 years 
 
17.6 (15) 
29.4 (25) 
23.5 (20) 
29.4 (25) 
 
30.3 (23) 
28.9 (22) 
19.7 (15) 
21.0 (16) 
0.2535 
Vitamin D intake 
Vitamin D supplement 
Multivitamin 
None 
 
24.7 (21) 
12.9 (11) 
62.3 (53) 
 
19.7 (15) 
15.8 (12) 
64.5 (49) 
0.7049 
Ca intake 
Ca supplement 
Multivitamin 
None 
 
27.1 (23) 
11.8 (10) 
61.2 (52) 
 
15.8 (12) 
14.5 (11) 
69.7 (53) 
0.2208 
Serum Ca level (median) 9.2  9.2  0.7859 
Number of comorbidity 
None 
1-5 (inclusive) 
> 5 
 
42.4 (36) 
48.2 (41) 
9.4 (8) 
 
48.7 (37) 
44.7 (34) 
6.6 (5) 
0.1658 
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Number of concomitant meds  
None 
1-5 (inclusive) 
> 5 
 
30 
49 
6 
 
33 
42 
1 
0.6509 
Number of AEDs, % (N) 
1 
2 
3 
4 
5 
 
32.9 (28) 
30.6 (26) 
24.7 (21) 
5.9 (5) 
5.9 (5) 
 
50.0 (38) 
30.3 (23) 
14.5 (11) 
2.6 (2) 
2.6 (2) 
0.1447 
Therapeutic category 
Monotherapy 
Polytherapy 
 
32.9 (28) 
67.1 (57) 
 
50 (38) 
50 (38) 
0.0280 
VNS 
Yes 
No 
 
16.5 (14) 
83.5 (71) 
 
5.3 (4) 
94.7 (71) 
0.0142 
Proportion of EIAEDs  
None 
~50% 
> 50% 
 
35.3 (30) 
42.3 (36) 
22.4 (19) 
 
60.5 (46) 
23.7 (18) 
15.8 (12) 
0.0053 
Proportion of high-dose AEDs  
None~50% 
> 50% 
> 50% 
 
29.4 (25) 
27.1 (23) 
43.5 (37) 
 
40.8 (31) 
21.0 (16)  
38.2 (29) 
0.3052 
BMI: Underweight (<18.5), normal weight (18.5–24.9), overweight (25–29.9) 
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Table 2 shows the association between ALP elevation and various factors. Based on the crude 
ORs, patients with uncontrolled seizures demonstrated 1.964 times higher odds of ALP elevation relative 
to the odds of ALP elevation among epilepsy patients with well-controlled seizures (95% CI: 1.049-
3.680, p=0.0341). Gender, therapeutic category (monotherapy vs. polytherapy), and proportion of 
EIAEDs also were significantly associated with ALP elevation. The number of comorbidity, the length of 
epilepsy, and the number of AEDs were considered potential confounders that significantly altered 
seizure status and OR of ALP elevation. A univariate analysis in a logistic regression model demonstrated 
that only seizure status, gender, therapeutic category, and proportion of EIAEDs showed a statistically 
significant association with ALP elevation. 
Previous reports showed that EIAEDs alter vitamin D metabolism and that vitamin D can alter 
the absorption of Ca from the intestine. Thus, the influences of vitamin D intake, Ca intake, serum Ca 
levels, and proportion of EIAEDs on seizure status and ALP elevation also were examined. No significant 
interactions were seen between vitamin D metabolism, Ca intake, and proportion of EIAEDs on the effect 
of ALP.  
Table 2. Univariate and multivariate logistic regression analysis for ALP elevation 
Risk factor Univariate Multivariate 
OR 95%CI P value OR 95%CI P value 
Seizure frequency 1.964 1.049 3.679 0.0350 1.732 0.811 3.700 0.1562 
Race 0.736 0.362 1.497 0.3973 0.736 0.331 1.636 0.4525 
Diagnosis 1.586 0.826 3.046 0.1658 1.493 0.707 3.151 0.2931 
Gender 0.339 0.178 0.645 0.0010 0.342 0.162 0.723 0.0050 
BMI 0.931 0.628 1.380 0.7216 0.977 0.614 1.555 0.9229 
Smoking 1.334 0.631 2.824 0.4508 1.952 0.793 4.801 0.1453 
Compliance  1.078 0.315 3.687 0.9043 0.981 0.223 4.312 0.9794 
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Number of comorbidity 1.564 0.892 2.745 0.1188 1.140 0.428 3.036 0.7930 
Number of concomitant 
medications 
1.263 0.769 2.074 0.3568 1.105 0.472 2.590 0.8180 
Length of epilepsy 1.313 0.988 1.745 0.0602 0.951 0.663 1.364 0.7858 
Vitamin D intake 0.902 0.620 1.311 0.5887 0.927 0.265 3.240 0.9054 
Calcium intake 0.743 0.507 1.091 0.1299 0.848 0.448 1.603 0.6112 
Therapeutic category 1.483 1.087 2.022 0.0129 1.325 0.900 1.950 0.1533 
Proportion of enzyme 
inducing AEDs 
1.408 1.065 1.861 0.0163 1.566 1.134 2.163 0.0064 
Proportion of high-dose 
AEDs 
1.250 0.873 1.788 0.2227 1.096 0.693 1.734 0.6957 
 
Table 3 shows a summary of the results of the final regression model. Variables in the regression 
model were selected based on prior evidence, clinically relevant factors, and the covariates that showed 
statistical significance upon univariate logistic regression analyses. The univariate logistic regression 
analysis was used to determine the final model. The variables that provided p values of less than 0.1 were 
selected in the final equation. The final model was as follows, and uncontrolled seizures, and higher 
proportion of EIAEDs were significant factors that elevated serum ALP levels: 
Logit (p) of ALP elevation = -0.2157+ 0.8465x uncontrolled seizure status + (-1.0610)x gender  + 0.5239x proportion of 
enzyme inducing AED 
Table 3. Logistic regression of factors associated with ALP elevation 
Parameter Estimate (β) SE P value OR 
 
95%  CI 
Intercept -0.2157 0.3340 0.5183   
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Uncontrolled seizures 0.8465 0.3445 0.0140 2.331 1.187-4.580 
Gender -1.0610 0.3436 0.0020 0.346 0.176-0.679 
Proportion of EIAEDs 0.5239 0.0.2227 0.0187 1.689 1.091-2.613 
 
B. Uncontrolled seizures and history of fracture 
The study cohort was a total of 161 patients: nine had at least one fracture in their lifetime and 
152 did not have fractures. The demographic characteristics were summarized in Table 4. The number of 
cases did not provide adequate power for the analyses of interest. No statistically significant differences 
were found between the cases and controls in all variables except with the serum Ca level (p=0.0127). 
The global null hypothesis test for β=0 was not rejected by the Likelihood Ratio test when conducting 
univariate and multivariate analysis with logistic regression. Serum Ca levels and the proportion of 
EIAEDs were the only variables that satisfied the regression model (p=0.0065 and 0.0488, respectively). 
The crude OR of serum Ca levels and the proportion of AED for the history of fractures were 0.101 (95% 
CI: 0.012-0.825, p=0.0134) and 2.360 (95% CI: 0.985-5.655, p=0.0542).  
Table 4. Characteristics of cases and control subjects (history of fracture) 
 Cases: positive history 
of fracture 
(N=9) 
Controls: negative 
history of fracture 
(N=152) 
P value 
Seizure status,  % (N) 
Seizure free 
Uncontrolled 
 
33.3 (3) 
66.7 (6) 
 
50.0 (76) 
50.0 (76) 
0.4959 
Age (median), years  36.0  32.0  0.1478 
Gender, % (N) 
Male 
Female 
 
44.4 (4) 
55.6 (5) 
 
56.6 (86) 
43.4 (66) 
0.5092 
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Diagnosis,  % (N) 
Partial 
Generalized 
Unclassified 
 
77.8 (7) 
11.1 (1) 
11.1 (1) 
 
80.9 (123) 
15.8 (24) 
3.3 (5) 
0.4088 
Race, % (N) 
White 
Black 
Others 
 
66.7 (6) 
33.3 (3) 
0 (0) 
 
83.5 (127) 
14.5 (22) 
2.0 (3) 
0.2884 
BMI, % (N) 
Underweight 
Normal 
Overweight 
 
44.4 (4) 
22.2 (2) 
33.3 (3) 
 
32.9 (50) 
38.8 (59) 
28.3 (43) 
0.6309 
Smoking,  % (N) 
Nonsmoker 
Smoker 
 
66.6 (6) 
33.3 (3)  
 
78.3 (119)  
21.7 (33) 
0.4196 
Medication compliance, % (N) 
≥ 80% 
< 80% 
 
100 (9) 
0 (0) 
 
92.8 (141) 
7.2 (11) 
1.0000 
Length of epilepsy, year 
1-10 years 
11-20 years 
21-30 years 
> 30 years 
 
11.1 (1) 
44.4 (4) 
11.1 (1) 
33.3 (3) 
 
24.3 (37) 
29.3 (43) 
22.4 (34) 
25.0 (38) 
0.6262 
Vitamin D intake   0.5360 
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Vitamin D supplement 
Multivitamin 
None 
22.2 (2) 
0 (0) 
77.8 (7) 
22.4 (34) 
15.1 (23) 
62.5 (95) 
Ca intake 
Ca supplement 
Multivitamin 
None 
 
22.2 (2) 
0 (0) 
77.8 (7) 
 
21.7 (33) 
13.8 (21) 
64.5 (98) 
0.7691 
Serum Ca level (median) 8.8  9.2  0.0127 
Number of comorbidity  
None: 
1-5 (inclusive) 
> 5 
 
22.2 (2) 
77.8 (7) 
0 (0) 
 
40.1 (61) 
55.3 (84) 
4.6 (7) 
0.5426 
Number of concomitant meds  
None 
1-5 (inclusive) 
> 5 
 
44.4 (4) 
55.6 (5) 
0 (0) 
 
45.4 (69) 
46.0 (70) 
8.5 (13) 
1.0000 
Number of AEDs, % (N) 
1 
2 
3 
4 
5 
 
33.3 (3) 
22.2 (2) 
22.2 (2) 
22.2 (2) 
0 (0) 
 
41.4 (63) 
30.9 (47) 
19.7 (30) 
3.3 (5) 
4.6 (7) 
0.1855 
Number of AEDs, % (N) 
Monotherapy  
 
3 (33.3) 
 
63 (41.5) 
0.7382 
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Polytherapy 6 (66.7) 89 (58.5) 
VNS 
Yes 
No 
 
22.2 (2) 
77.8 (7) 
 
10.6 (16) 
89.4 (135) 
0.2675 
Proportion of EIAEDs  
None 
0-50% 
> 50% 
 
22.2 (2) 
33.3 (3) 
44.4 (4) 
 
48.7 (74) 
33.5 (51) 
17.8 (27) 
0.1056 
Proportion of high-dose AEDs  
None 
0-50% 
> 50% 
 
11.1 (1) 
33.3 (3) 
55.6 (5) 
 
36.2 (55) 
23.7 (36) 
40.1 (61) 
0.3080 
ALP (continuous, median)  81.0  70.0  0.0811 
ALP (categorical) 
ALP<70 
ALP≥70 
 
33.3 (3) 
66.7 (6) 
 
48.0 (73) 
52.0 (79) 
0.5017 
 
Discussion 
Our study population showed an association between uncontrolled seizures and ALP elevation, 
indicating that frequent seizures alter bone metabolism. However, other factors, such as therapeutic 
category, proportion of EIAEDs, and a combination of those factors with uncontrolled seizure status may 
result in ALP elevation. To the best of our knowledge, this is the first study to determine the relationship 
between seizure frequency and bone metabolism among ambulatory epilepsy patients treated with one or 
more AED. Published studies showed that AED treatment results in an elevation of ALP or bone ALP 
when compared to epilepsy patients with health population.
10-17,19-27,50
  Our study identified another risk 
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factor--uncontrolled seizure condition--that altered the bone metabolism among epilepsy patients. 
However, in our study, uncontrolled seizures did not increase the risk of fracture. The small number of 
patients (n=9) with fractures may explain the negative finding in our study. 
One possible mechanism for why uncontrolled seizures can be a significant risk factor of 
alteration of bone metabolism is that frequent seizures alter excretion of sex hormones, such as estrogens 
and androgens. Prior studies indicated that seizures interfere with the regulation of hormone release via 
the hypothalamus-pituitary-endocrine organ axis, resulting in hypogonadism, sexual dysfunction, 
infertility, and osteoporosis.
41, 51-53
 Indeed, sex hormones are essential in maintaining adequate bone 
density.
39,54,55
 Androgens are known to be crucial in bone formation, because androgens increase 
osteoblast activity.
55,56
  The long-term testosterone therapy increased bone mineral density (BMD) by 
26% (p<0.0001) compared to the BMD before therapy.
56
 Estrogen enhances osteoblast activities but 
decreases the lifespan of osteoclasts.
39,54,57-60
 In fact, the Women’s  ealth Initiative’s randomized 
controlled trial showed that estrogen replacement therapy decreased the risk of hip fracture (hazard ratio: 
0.66, 95% CI: 0.45-0.98) compared to individuals who did not undergo estrogen replacement therapy.
61
 
Additionally, men and women with epilepsy tend to experience a reduction of gonadotropin and sex 
hormones as well as a higher serum concentration of sex hormone-binding globulin (SHBG).
 41, 83-85
 This 
illustrates that epilepsy patients with uncontrolled seizures may induce less biologically available free-sex 
hormones (i.e., unbound sex hormones to SHBG). Additionally, estrogen is known to enhance the 
conversion from 25-hydroxy vitamin D3, the intermediate metabolite of active vitamin D3, to 1α,25-
(OH)2D3, the active vitamin D3, and also known to inhibit the conversion from 25-hydroxy vitamin D3 to 
24,25-dihydrovitamin D3, inactive metabolite of vitamin D.
62
 Therefore, an uncontrolled seizure status 
may induce an inadequate production of sex hormones, a low concentration of biologically available sex 
hormone, and active vitamin D production, which subsequently altered bone metabolism.           
Our study showed that the crude OR of EIAED used for ALP elevation was 1.408 (95% CI: 
1.065-1.861, p=0.0163). That is an indication that poor bone health is positively associated with a 
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proportion of EIAED use. Carbamazepine (CBZ), phenytoin (PHT), phenobarbital (PB), and primidone 
(PRM) are known as EIAEDs.
63,64
 Although our data did not show significant differences in serum Ca 
levels between ALP elevated and non-ALP elevated groups, a published study showed that EIAEDs 
increased vitamin D metabolism, which leads to lower serum calcium levels and to an enhancement of 
parathyroid hormone release.
46
 Additionally, some EIAEDs altered bone resorption markers (e.g., cross-
linked C-telopeptide, cross-linked N-telopeptides of type I collagen levels), and bone formation markers 
(i.e., elevation of ALP or bone-specific ALP, osteocalcin, C-terminal propeptide of Type I procollagen, 
N-terminal propeptide of Type III procollagen, and N-terminal propeptide of Type I 
procollagen).
27,28,35,50,65-74
  
Another significant aspect in EIAED use is recognizing the roles of nuclear receptors in CYP450 
regulation. The nuclear receptors are essential in understanding how isoenzymes are related to bone 
metabolism. Recently, the roles of nuclear receptors in CYP450 regulation have been widely 
known.
38,75,76
 CBZ and PHT bind to specific nuclear receptors, such as the constitutive androstane 
receptor (CAR) and the pregnane X receptor (PXR), which induce CYP1, CYP2, and CYP3 isoenzymes, 
resulting in enhancement of steroid metabolism.
38,75,76
  We discussed that uncontrolled seizures may 
reduce the quantity of the biologically available sex hormone. Adding the fact that estrogens and 
androgens increase the survival of osteocyte but reduce the lifespan of osteoclasts,
39,54,57-60
 the use of 
EIAEDs accelerates the loss of sex hormones by enhanced metabolism of these hormones.   
Nuclear receptors also are responsible in vitamin D metabolism for maintaining healthy bones. In 
the CYP family, the CYP24 isoenzyme converts 25-hydroxy vitamin D3 to 24,25-dihydrovitamin D3 and 
1α, 24,25-trihydrovitamin D3, the inactive metabolites of vitamin D3.
76
 Valproic acid binds to the vitamin 
D receptor and induces the CYP24 isoenzyme.
77
 This enzyme induction due to valproic acid results in an 
increase of inactive forms of vitamin D3 and of bone loss.
77
 
In our study, no differences were found in the degree of vitamin D and Ca intake and the serum Ca 
levels between patients with or without ALP elevation. This indicates that our study sample did not have 
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hypocalcemia and that vitamin D and Ca supplementation did not make significant differences in serum 
Ca levels between the two groups. However, interestingly, when controlling for vitamin D intake (patients 
who took a vitamin D supplement of at least 400 IU/day or more, N=36), patients with uncontrolled 
seizures showed higher OR for ALP elevation compared to seizure-free patients (OR= 5.0000, 95% CI: 
1.1949-20.9218, p=0.0233). But patients who took multivitamins or no vitamin D supplement did not 
show significant differences in ALP elevation (OR= 2.4500, 95% CI: 0.4561-13.1605, p= 0.2921, N=23; 
OR= 1.3745, 95% CI: 0.6304-2.9973, p= 0.4233, N=102, respectively). No association was found 
between vitamin D and Ca intake, the proportion of EIAED use, and serum vitamin D levels (p>0.05). 
We expected that higher vitamin D intake might show lower ALP levels, but the result was the opposite 
of the expectation.  
Several reasons may explain this result, and these might be related to the limitations of this study. 
One possible reason is that patients using a vitamin D supplement might not have been on the supplement 
for enough time to receive the benefit from it in this cross-sectional study design. Because we did not 
capture the duration of the supplements during the chart review, we did not examine the influence of the 
duration of the supplementation on seizure status and ALP elevation. Some of the clinical studies to 
investigate the efficacy of vitamin D supplements spent at least 60 days evaluating the efficacy.
74,78-80
 
Additionally, the amount of vitamin D in this study might not be enough to correct bone abnormalities. In 
fact, the range of vitamin D administration was between 2,000 IU and 120,000 IU in the clinical trials 
with epilepsy patients treated with AEDs.
74,78-80
 Moreover, we did not capture the compliance rate of the 
vitamin D and Ca supplement during our chart review. Thus, it is unclear if all patients who reported 
positive vitamin D supplementation truly took the supplement. Another reason might be that vitamin D 
intake might not correlate to serum vitamin D levels. We did capture serum vitamin D levels during data 
collection. However, only nine of 161 epilepsy patients had serum vitamin levels on the charts. This made 
it impossible to investigate the influence of uncontrolled seizures and vitamin D intake on serum vitamin 
D levels. 
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Other limitations of this study were hormone levels (estrogens, androgens, and vitamin D) and 
other biomarkers that determine bone health status, such as bone-specific ALP and BMD data from 
DEXA scan, both of which were not available. Additionally, the duration of AED therapy and vitamin D 
and Ca supplementation were not available to confirm bone damage. Additionally, the ALP level was 
measured within a year from the last clinic visit, which might not directly reflect the adverse reactions 
from the AEDs with which patients were treated or from the seizure status at the latest clinic visit. 
In summary, an uncontrolled seizure condition is negatively associated with bone health. The 
mechanism of how uncontrolled seizures affect bone health is unclear, but an abnormal excretion of sex 
hormones and vitamin D metabolism may influence the structure of the bones. Further investigation is 
necessary to confirm this hypothesis. Additionally, healthcare providers should pay attention to bone 
health, especially when seizures are uncontrollable even with adequate AED treatment. Routine analysis 
of serum ALP is convenient and can be significant to detect the alteration of bone metabolism. 
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